Abbott, Teva Settle Patent Dispute Over TriCor, But Antitrust Claims Remain

Law360, New York (June 9, 2005, 12:00 AM EDT) -- Abbott Laboratories has settled a patent dispute with Israeli drug maker Teva Pharmaceutical Industries Ltd. over a generic version of Abbott's best-selling cholesterol treatment TriCor.

Abbott said the litigation had been amicably resolved and the parties have agreed to dismiss the patent claims, allowing Teva to go ahead with the launch of a generic TriCor.

However, Abbott said Teva's generic drug would be the equivalent of Abbott's older formulation of TriCor, not the newer formulation that Abbott has been marketing since getting Food and Drug Administration...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.